Ingersoll Rand (IR) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and performance

• Achieved $7.5B in revenue, 27% EBITDA margin, and 17% free cash flow margin, with a $34B market cap.

• Since 2017, delivered over 330% total shareholder return and double-digit EPS CAGR despite industry headwinds.

• 37% of revenue comes from consumable aftermarket, with strong positions in industrial and life science technologies.

• Improved EBITDA margins by 600+ basis points in five years through the IRX operating system.

• Created $30B in shareholder value and outperformed S&P and industry peers.

Strategic growth and M&A

• Acquired 76 companies in five years, focusing on founder-led, family-owned businesses.

• M&A flywheel enables annual bolt-on acquisitions, typically at 9x pre-synergy multiples, reduced post-integration.

• Life science exposure grew from 4% in 2020 to 18% in 2024, with further expansion targeted.

• Active pipeline of about 100 companies, with 10 in active discussions at any time.

• Four life science deals in the past year, averaging 10x EBITDA multiples and targeting mid-teens ROIC within three years.

Life science technologies platform

• Platform includes brands like ILC Dover and Flexan, serving pharma, biopharma, and medtech markets.

• Focus areas: flow control solutions, biopharma/pharma solutions, and medical device solutions.

• 85% of revenue is recurring consumables, with highly specified products integrated into customer applications.

• Positioned in high-growth segments: weight loss therapies, oncology, minimally invasive procedures, and diagnostics.

• Global footprint with scale in North America, Europe, and growing presence in Asia.